I am pretty sure this has been stated before but if:
Annual Paediatric Market for aGVHD refractory to all other treatments ~ 2000 cases per year
@ $200k treatment = $400m annualised potential revenue
@ $400k treatment = $800m annualised potential revenue
@ $600k treatment = $1.2b annualised potential revenue
If i use a super conservative 10 x PE to establish a potential valuation (noting that the industry is apparently trading at PE of 45.8 (see below)
Then would it be fair to say conservatively, that approval of aGVHD might result in a valuation range of :
@ $200k treatment = $400m x 10 = $4b or ~$3.50 /share
@ $400k treatment = $800m x 10 = $8b or ~$7.00 /share
@ $600k treatment = $1.2b x 10 =$12b or $10.50/share
Even with a PE of 5, the numbers still appear pretty hard to get my head around.
Of course there are some important hurdles to overcome before any of this could be realised and my logic might be way off
good luck all
DYOR and not investment advice
V
- Forums
- ASX - By Stock
- Presentation on ASX Gems Conference on 21st June
I am pretty sure this has been stated before but if:Annual...
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2482 | $1.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.46 | 27045 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2482 | 1.450 |
1 | 2574 | 1.440 |
1 | 15000 | 1.435 |
2 | 11400 | 1.430 |
1 | 15000 | 1.425 |
Price($) | Vol. | No. |
---|---|---|
1.455 | 14000 | 1 |
1.460 | 14000 | 1 |
1.465 | 14000 | 1 |
1.480 | 50134 | 1 |
1.485 | 40331 | 2 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |